Broadview Ventures appeared to be the VC, which was created in 2008. The leading representative office of defined VC is situated in the Boston. The fund was located in North America if to be more exact in United States.
Comparing to the other companies, this Broadview Ventures performs on 17 percentage points less the average number of lead investments. The higher amount of exits for fund were in 2017. The fund is constantly included in 2-6 deals per year. Speaking about the real fund results, this VC is 1 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2014. Despite it in 2019 the fund had an activity. Deals in the range of 1 - 5 millions dollars are the general things for fund. When the investment is from Broadview Ventures the average startup value is 5-10 millions dollars.
The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the Broadview Ventures, startups are often financed by Boulder Ventures, Atlas Venture, Amgen Ventures. The meaningful sponsors for the fund in investment in the same round are Boulder Ventures, Atlas Venture, Amgen Ventures. In the next rounds fund is usually obtained by Remeditex Ventures, Boulder Ventures, Atlas Venture.
Among the most popular portfolio startups of the fund, we may highlight 480 Biomedical, Capricor Therapeutics, InfoBionic. The fund has no exact preference in some founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Among the most successful fund investment fields, there are Therapeutics, Medical Device. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
The fund was created by Christopher Colecchi. The overall number of key employees were 6.
Funds with similar focus
|Asukanet||Hiroshima, Hiroshima Prefecture, Japan|
|Chuangkun Investment Management||China, Hangzhou, Zhejiang|
|Industrial Securities||China, Fuzhou, Jiangxi|
|Nanosys||California, Milpitas, United States|
|Shanghai Zheshang Shangwu Zixun Youxian Gongsi||China, Shanghai|
|SnowMark Corporation||Florida, United States, Vero Beach|
|The Provident Bank||Amesbury, Massachusetts, United States|
|ZEMU Venture Capital||-|
|$10M||31 Aug 2022||Miami, Florida, United States|
|$30M||05 May 2022||Union City, California, United States|
|$5M||09 Feb 2022||Lausanne, Vaud, Switzerland|
|$9M||04 Feb 2022||Dublin, County Dublin, Ireland|
|$3M||12 Jul 2021||Concord, New Hampshire, United States|
|$15M||23 Jun 2021||Miami, Florida, United States|
|$17M||01 Jun 2021||Bordeaux, New Aquitaine, France|
|$19M||20 May 2021||Lausanne, Vaud, Switzerland|
|$5M||07 Dec 2020||Durham, North Carolina, United States|
– RapidPulse from Miami FL raised $15M in Series A funding.
– The round was led by Santé Ventures with participation from Epidarex Capital, Hatteras Venture Partners, Broadview Ventures, and Syntheon.
– The company plans to use the funds to advance its system through expanded clinical evaluation and build out its platform of proprietary catheters.
– HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), announced the successful closing of its CHF 18 million seed round.
– The financing was led by Broadview Ventures, with participation from Apollo Health Ventures, BERNINA BioInvest, 4See Ventures, Schroder Adveq and Viva BioInnovator.
– Founded and led by a team of experts in lncRNA biology and fibrotic disease, HAYA will use the funds from the financing to advance the discovery and development of innovative organ and cell-selective therapeutics that target lncRNAs to treat and potentially reverse fibrosis and other serious medical conditions related to aging.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.